Delta Air Lines after raising its Q4 outlook and issuing FY23 guidance Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Avidity Biosciences (RNA) up 38% after announcing AOC 1001 data from the preliminary assessment of the Phase 1/2 MARINA trial demonstrating the first-ever successful targeted delivery of RNA into muscle, a revolutionary advancement for the field of RNA therapeutics
- Kymera Therapeutics (KYMR) up 39% after announcing clinical results from the patient cohort portion of its KT-474 Phase 1 clinical trial, as well as updates on its three oncology programs: KT-413, KT-333 and KT-253
- Delta Air Lines (DAL) up 4% after providing guidance for FY22, FY23 and FY24 at its investor event
UP AFTER EARNINGS -
- Aspen Group (ASPU) up 9%
- Rev Group (REVG) up 7%
LOWER -
- Best Buy (BBY) down 4% after BofA analyst Elizabeth Suzuki downgraded shares to Underperform from Neutral with a price target of $69, down from $80
- Charter (CHTR) down 10% after the company's price target was slashed at three separate firms following its investor day
- Tesla (TSLA) down 1% after Goldman Sachs analyst Mark Delaney lowered the firm's price target on the stock to $235 from $305 but kept a Buy rating on the shares
Symbols:
DAL KYMR RNA REVG ASPU TSLA BBY CHTR Keywords: Fly Intel, Wall Street, Top Stories, Stocks